9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
Open accessThe DOI matches its Crossref record; 82 of the 84 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc20-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc20-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given the demonstrated benefits of SGLT2 inhibitors, the updated American Diabetes Association guidelines10 and the American College of Cardiology expert consensus statement11 now recommend their use for diabetic patients who have or are at high risk for cardiovascular disease, CKD, or heart failure regardless of current glycemic control.”
From Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US (2021) · cites this paper as [10]
In the citing paper
“All recommend SGLT2 inhibition for patients with T2DM and eGFR as low as 30 mL/min/1.73 m2, particularly if severely increased albuminuria is present.”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [85]
In the citing paper
“Major national and international organizations are rapidly updating recommendations and guidelines (Table 4) (85–88).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [85]
In the citing paper
“In the US, the 2020 national median drug acquisition cost of GLP-1RAs ranges from $634 per month to $835 per month,27·41 although the out-of-pocket cost borne by patients varies considerably by insurance formulary and coverage.”
From Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review (2020) · cites this paper as [27]
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“may reduce risk of cardiovascular events and death (35).”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M. B., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 965
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682 · cited 1×
“first-line therapy hasbeneficial effects on A1C, weight, and cardiovascular mortality (36); there is little systematic data”
BackgroundThreshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 1×
“with type 1 diabetes (15,16), and recent evidence suggests that a closed-loop system is superior to sensor-augmented pump therapy for glycemic control and reduction of hypoglycemia over 3 months of comparison in children and adults with type 1 diabetes (17).”
BackgroundHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00336 · Cited by 609
Research works printed but not linked: 1
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
Cited by
Items 401–500 of 958
Ambulatory noninsulin treatment of type 2 diabetes mellitus in the United States, 2015 to 2019
Heyward, J., Christopher, J., Sarkar, S., Shin, J., Kalyani, R. R., & Alexander, G. C. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14408 · Cited by 16
Using the Surgical Risk Preoperative Assessment System to Define the “High Risk” Surgical Patient
Dyas, A. R., Bronsert, M. R., Meguid, R. A., Colborn, K. L., Lambert‐Kerzner, A., Hammermeister, K. E., Rozeboom, P. D., Velopulos, C. G., & Henderson, W. G. (2021) · Journal of Surgical Research · doi:10.1016/j.jss.2021.08.045 · Cited by 13
Sodium, Glucose and Dysregulated Glucagon Secretion: The Potential of Sodium Glucose Transporters
Armour, S. L., Frueh, A., & Knudsen, J. G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.837664 · Cited by 13
Nashawi, M., Sheikh, O., Battisha, A., Ghali, A. N., & CHILTON, R. J. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-10046-w · Cited by 13
Yang, C., Lin, W., Li, L., Ou, H., & Kuo, S. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2262 · Cited by 14
Giugliano, D., Longo, M., Scappaticcio, L., Caruso, P., Gicchino, M., Petrizzo, M., Bellastella, G., Maiorino, M. I., & Esposito, K. (2023) · Endocrine · doi:10.1007/s12020-023-03547-9 · Cited by 12
Liu, J., Su, X., Hao, Y., Liu, J., Cardio Metabolic Survey investigators, Zhang, Y., Zhang, Y., Zhong, Z., Li, J., Nie, Y. J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-69016-z · Cited by 14
“Despite national and international guidelines and expert consensus 6,8,17–19 indicate that GLP-1RA or SGLT2 inhibitors with proven CV benefits should be added in patients with T2DM and established ASCVD or at high risk for ASCVD, even if glucose is controlled, they are underused in real world…”
BackgroundMphasha, M. H., & Vagiri, R. V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020624 · Cited by 14
“The quantity and quality of carbohydrates ingested directly influence insulin requirements, making precise insulin dosing a cornerstone of effective diabetes management [51,52].”
New Onset Diabetes After Organ Transplantation: Risk Factors, Treatment, and Consequences
Popović, L., & Bulum, T. (2025) · Diagnostics · doi:10.3390/diagnostics15030284 · Cited by 17
“Although some studies report benefits consistent with findings in the non-transplant population and a similar frequency of adverse effects compared to transplant patients not receiving SGLT-2 inhibitors, caution is advised, given the limited data available [64,88–91].”
Pantalone, K. M., Munir, K. M., Hasenour, C. M., Atisso, C. M., Varnado, O. J., Maldonado, J. M., & Кониг, М. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14165 · Cited by 12
Hunt, L. M., Arndt, E., Bell, H. S., & Howard, H. (2021) · Journal of Bioethical Inquiry · doi:10.1007/s11673-021-10119-x · Cited by 13
Ekusheva, E. V., Ших, Е. В., As, A., Ostroumova, O. D., Zaharov, V. V., Живолупов, С. А., & Djukic, M. (2021) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202112111117 · Cited by 13
One hundred years of insulin: Is it time for smart?
Gilor, C., & Fleeman, L. M. (2022) · Journal of Small Animal Practice · doi:10.1111/jsap.13507 · Cited by 13
Puspaningtyas, D. E., Nekada, C. D. Y., & Sari, P. M. (2022) · AcTion Aceh Nutrition Journal · doi:10.30867/action.v7i2.738 · Cited by 12
Risk stratification tools for heart failure in the diabetes clinic
Cannistraci, R., Mazzetti, S., Mortara, A., Perseghin, G., & Ciardullo, S. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.03.022 · Cited by 13
Assessment of clinical inertia in people with diabetes within primary care
Meredith, A. H., Buatois, E. M., Krenz, J. R., Walroth, T., Shenk, M., Triboletti, J. S., Pence, L., & Gonzalvo, J. D. (2021) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.13429 · Cited by 12
Herold, Z., Herold, M., Rosta, K., Doleschall, M., & Somogyi, A. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00569-5 · Cited by 12
John, M., Kalra, S., & Nair, T. (2020) · Indian Heart Journal · doi:10.1016/j.ihj.2020.07.009 · Cited by 13
Inpatient and Outpatient Technologies to Assist in the Management of Insulin Dosing
Cui, L., Schroeder, P. R., & Sack, P. (2020) · Clinical Diabetes · doi:10.2337/cd20-0054 · Cited by 12
“10%, or blood glucose levels are very elevated ( $ 300 mg/dL) (33).”
BackgroundImpact of a diabetes remote monitoring program on medication adherence
Munshi, K. D., Amelung, K., Carter, C. S., James, R. A., Shah, B. R., & Henderson, R. R. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.6.724 · Cited by 12
Lyu, B., Grams, M. E., Chang, A. R., Inker, L. A., Coresh, J., & Shin, J. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.11.013 · Cited by 12
Cavallari, I., Maddaloni, E., Pieralice, S., Mulè, M. T., Buzzetti, R., Ussia, G. P., Pozzilli, P., & Grigioni, F. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa427 · Cited by 12
Cha-Silva, A. S., Chen, Y., Fazioli, K., Rivara, M. B., & Devine, E. B. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa894 · Cited by 12
Vázquez-Agra, N., Marques-Afonso, A.-T., Cruces‐Sande, A., Novo‐Veleiro, I., Pose‐Reino, A., Méndez‐Álvarez, E., Soto‐Otero, R., & Ameijeiras, Á. H. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268871 · Cited by 11
Shikamura, M., Takayama, A., Takeuchi, M., & Kawakami, K. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15632 · Cited by 12
“21,22 2 | MATERIALS AND METHODS”
Khadour, F. A., Khadour, Y. A., Alhatem, W., & Albarroush, D. (2024) · Scientific Reports · doi:10.1038/s41598-024-67326-w · Cited by 12
“In the past, the primary focus for patients with T2DM was on glycemic control through lifestyle modifications and traditional antidiabetic medications, such as metformin, sulfonylureas, and insulin 36,37 .”
BackgroundFeng, W., Wang, W., Meng, R., Wu, G., Zhang, M., Zhang, X., Yin, H., & Zhu, D. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002290 · Cited by 13
Tang, E. H. M., Wong, C. K. H., Lau, K. T. K., Fei, Y., & Cheung, B. M. Y. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109071 · Cited by 11
Liu, D., Du, Y., Yao, X., Wei, Y., Zhu, J., Cui, C., Zhou, H., Xu, M., Li, H., & Ji, L. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101185 · Cited by 11
Farooqi, M. H., Abdelmannan, D. K., AlBuflasa, M., Hamed, M. A. A., Xavier, M., Cadiz, T. J. S., & Nawaz, F. A. (2022) · International Journal of Clinical Practice · doi:10.1155/2022/6286574 · Cited by 13
“*e current international guidelines recommend routine consultations every three months for patients with T2DM, particularly for poorly controlled patients [25].”
Franch-Nadal, J., Granado-Casas, M., Mata-Cases, M., Ortega, E., Vlacho, B., & Mauricio, D. (2022) · Primary Care Diabetes · doi:10.1016/j.pcd.2022.10.005 · Cited by 12
Hyperglycemia in Turner syndrome: Impact, mechanisms, and areas for future research
Mitsch, C., Alexandrou, E., Norris, A. W., & Pinnaro, C. T. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1116889 · Cited by 16
Yuan, S., & Wu, Y. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1201818 · Cited by 11
An Update on Semaglutide Research: A Bibliometric Analysis and a Literature Review
Dagli, N., Kumar, S., Ahmad, R., Narwaria, M., & Haque, M. (2023) · Cureus · doi:10.7759/cureus.46510 · Cited by 16
Contemporary Medical Management of Peripheral Arterial Disease
Cook, I. O., & Chung, J. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07516-2 · Cited by 16
“The 2020 American Diabetes Association guidelines on the management of pharmacotherapy propose an algorithm on drug choice in patients at risk for cardiovascular disease [46].”
Dahiru, M. M., & Musa, N. (2024) · Ankara Universitesi Eczacilik Fakultesi Dergisi · doi:10.33483/jfpau.1354293 · Cited by 11
Cowart, K., Updike, W. H., & Pathak, R. (2021) · Clinical Diabetes · doi:10.2337/cd20-0080 · Cited by 11
SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives
Garla, V. V., Butler, J., & Lien, L. F. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01486-3 · Cited by 13
Васильевна, Ц. О., & Васильевна, В. В. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4436 · Cited by 11
Xiao, D., Liu, J., Zhang, S., Liu, R., Yin, J., Han, X., Li, X., Zhang, W., Chen, X., Zhou, H., et al. (2021) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s305020 · Cited by 11
Eghbali‐Zarch, M., Tavakkoli-Moghaddam, R. R., Esfahanian, F., & Masoud, S. (2022) · Medical & Biological Engineering & Computing · doi:10.1007/s11517-022-02602-3 · Cited by 11
Garg, S. K., Wernicke‐Panten, K., Wardęcki, M., Kramer, D., Delalande, F., Franek, E., Sadeharju, K., Monchamp, T., Miossec, P., Mukherjee, B., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0008 · Cited by 11
Kadowaki, T., Haneda, M., Ito, H., Sasaki, K., & Yamada, Y. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01306-0 · Cited by 12
Dulaglutide and Insulin: How Can the AWARD Studies Help Guide Clinical Practice?
MacIsaac, R. J. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00863-5 · Cited by 13
Cardiovascular safety outcomes of once‐weekly GLP‐1 receptor agonists in people with type 2 diabetes
Goldman, J. D. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13226 · Cited by 11
Hashemi, P., & Pezeshki, S. (2021) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2021.1925294 · Cited by 11
Di Molfetta, S., Bosi, E., Ceriello, A., Cucinotta, D., Tiengo, A., Scavini, M., Piccolo, C., Bonizzoni, E., Acmet, E., & Giorgino, F. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109070 · Cited by 10
Bando, H. (2020) · MOJ Clinical & Medical Case Reports · doi:10.15406/mojcr.2020.10.00341 · Cited by 10
Xiang, A. S., Szwarcbard, N., Gašević, D., Earnest, A., Pease, A., Andrikopoulos, S., Wischer, N., Davis, W. A., & Zoungas, S. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14506 · Cited by 11
Jafar, A., & Pasqua, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15463 · Cited by 11
Kim, C., Kim, Y., Sohn, J., Sung, J. H., Han, S., Lee, M., Kim, Y., Lee, J. J., Mo, H., Yu, K., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12040745 · Cited by 10
“Metformin (MET) is an oral antidiabetic drug widely used as a first-line treatment for type 2 DM [7,8].”
BackgroundReddiar, S. B., Abdallah, M., Styles, I. K., Müllertz, O. O., & Trevaskis, N. L. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114339 · Cited by 10
Oral Anaerobutyricum soehngenii augments glycemic control in type 2 diabetes
Attaye, I., Witjes, J. J., Koopen, A. M., van der Vossen, E. W. J., Zwirs, D., Wortelboer, K., Collard, D., Kemper, E. M., Winkelmeijer, M., Holst, J. J., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110455 · Cited by 11
“35 The fact that this study already provided significant findings following short-term A. soehngenii supplementation on glu-cometabolic control indicates the potential of A. soehngenii as an add-on therapy in the standard of care for T2D.”
Loganadan, N. K., Huri, H. Z., Vethakkan, S. R., & Hussein, Z. B. (2020) · Pharmacogenomics · doi:10.2217/pgs-2019-0171 · Cited by 12
Nguyen, J. V., Roseberry, S., Rivas, J. A., & Cauthon, K. A. B. (2021) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2021.112 · Cited by 10
Rachpirom, M., Barrows, L. R., Thengyai, S., Ovatlarnporn, C., Sontimuang, C., Thiantongin, P., & Puttarak, P. (2021) · Pharmacognosy Research · doi:10.5530/pres.14.1.13 · Cited by 16
Peng, Y., Xu, P., Shi, J., Zhang, Y., Wang, S., Zheng, Q., Wang, Y., Ke, T., Li, L., Zhao, D., et al. (2022) · Journal of Diabetes · doi:10.1111/1753-0407.13245 · Cited by 10
Dagogo-Jack, S. E., Cannon, C. P., Cherney, D. Z. I., Cosentino, F., Liu, J., Pong, A., Gantz, I., Frederich, R. C., Mancuso, J. P., & Pratley, R. E. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14691 · Cited by 10
Erdem, S., Titus, A., Patel, D., Patel, N. N., Sattar, Y., Glazier, J., & Alraies, C. M. (2023) · Cureus · doi:10.7759/cureus.37310 · Cited by 11
Tibaldi, J. M., Mercado, M. E., & Strong, J. L. (2020) · Clinical Diabetes · doi:10.2337/cd20-0014 · Cited by 10
Kalra, S., Unnikrishnan, A., Bantwal, G., Das, S., Polavarapu, N. K., & Gaurav, K. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01002-4 · Cited by 10
Das, A. K., Shah, S., Singh, S. K., Juneja, A., Mishra, N. K., Dasgupta, A., Deka, N., Abhyankar, M., & Revankar, S. Y. (2021) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514211030513 · Cited by 11
Cox, E. J., Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2020) · US Endocrinology · doi:10.17925/use.2020.16.2.80 · Cited by 10
Yip, T. C., Chan, R. N. C., Wong, V. W., Tse, Y., Liang, L. Y., Hui, V. W., Zhang, X., Li, G., Chan, H. L., & Wong, G. L. (2021) · Health Science Reports · doi:10.1002/hsr2.352 · Cited by 9
Cai, C., Gu, C., Meng, C., He, S., Lhamo, T., Draga, D., Zheng, Z., & Qiu, Q. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03777-0 · Cited by 9
“Metformin has become a first-line anti-hyperglycemic agent for patients newly diagnosed with type 2 diabetes, especially those with obesity [1].”
Kim, S. H., Chang, T. I., & Mahaffey, K. W. (2020) · Cardiology and Therapy · doi:10.1007/s40119-020-00190-7 · Cited by 9
Hong, T., Su, Q., Li, X., Shan, Z., Chen, L., Peng, Y., Chen, L., Yan, L., Bao, Y., Lyu, Z., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3416 · Cited by 11
Erectile Dysfunction Severity: The Role of Glycometabolic Compensation and Antihyperglycemic Drugs
Zamponi, V., Defeudis, G., Federico, F., Faggiano, A., & Mazzilli, R. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11237214 · Cited by 13
Boddepalli, C. S., Gutlapalli, S. D., Lavu, V. K., Abdelwahab, R. A. M., Huang, R., Potla, S., Bhalla, S., AlQabandi, Y., Nandula, S. A., & Khan, S. (2022) · Cureus · doi:10.7759/cureus.32286 · Cited by 12
Therapeutic Effects of Amaranth: Analysis of the Antidiabetic Potential of the Plant
Herrera, A. C., Zamudio, F. V., & Campos, M. R. S. (2024) · Journal of Medicinal Food · doi:10.1089/jmf.2022.0159 · Cited by 9
“27 These pathologies represent the main CD risk factors and a frequent cause of mortality and morbidity in the population with T2D 19 ; a healthy diet combined with the intake of functional foods can help to minimize or even prevent CD. 8 Evidence shows that amaranth extracts also contain favorable effects for CD-rela…”
InfluentialImproving the stability of insulin through effective chemical modifications: A Comprehensive review
Kamelnia, R., Ahmadi‐hamedani, M., Darroudi, M., & Kamelnia, E. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124399 · Cited by 9
Napoli, R., Formoso, G., Piro, S., Targher, G., Consoli, A., & Purrello, F. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.07.012 · Cited by 9
Yang, C., Lin, W., Su, P., Li, L., Yang, C., Ou, H., & Kuo, S. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2058 · Cited by 9
Lin, M.-H., Yang, H., Yen, C., Wu, C., Jenq, C., Kuo, G. C., Peng, W.-S., Liu, J., Tian, Y.-C., Yang, C.-W., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113578 · Cited by 11
“Upon these side effects, edema, weight gain and heart failure were concerned by most clinicians with little controversy [9, 31, 33].”
BackgroundInfluentialZimner‐Rapuch, S., Divino, V. M., Norrbacka, K., Boye, K. S., Lebrec, J., Rosilio, M., DeKoven, M., & Guerci, B. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01055-5 · Cited by 10
Hung, H., Chan, E. Y. Y., Chow, E., Chung, G. K.-K., Lai, F. T. T., & Yeoh, E. (2021) · Health & Social Care in the Community · doi:10.1111/hsc.13415 · Cited by 9
Alam, M. S., Kamrul-Hasan, A. B. M., & Kalam, S. T. (2021) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_2388_20 · Cited by 9
Wang, W., Sun, Y., Wang, S., & Sun, Y. (2021) · Endocrine Research · doi:10.1080/07435800.2021.1967376 · Cited by 9
Frías, J. P., Maaske, J., Suchower, L. J., Johansson, L., Hockings, P. D., Iqbal, N., & Wilding, J. P. H. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14548 · Cited by 9
Controversies in Gestational Diabetes
Zera, C., & Seely, E. W. (2021) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2021.17.2.102 · Cited by 10
Glycemic Control and Management in Pharmacist-Led Diabetic Clinic vs. Physician-Led Diabetic Clinic
Alghadeer, S. M., Alsuwayni, B. M., Almuwayjid, A. K., Almadi, M. S., Mubarak, A. M., bin Khunayn, R. M., & Al-Arifi, M. N. (2021) · Medicina · doi:10.3390/medicina58010014 · Cited by 10
Ruan, Z., Jiang, Y., Shi, H., Jia, R., Ung, C. O. L., & Hu, H. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2174099 · Cited by 9
“As recommended in the guideline of American Diabetes Association, GLP-1RA was a class of antidiabetic drugs which conferred lower hypoglycemia risk [54].”
Ogunsanmi, D., Harrison, A., Pakker, A. R., Kovesdy, C. P., Bailey, J. E., & Surbhi, S. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.6.699 · Cited by 10
Characterizing the weight-glycemia phenotypes of type 1 diabetes in youth and young adulthood
Kahkoska, A. R., Nguyen, C. T., Jiang, X., Adair, L. S., Agarwal, S., Aiello, A. E., Burger, K. S., Buse, J. B., Dabelea, D., Dolan, L. M., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000886 · Cited by 9
Pitlick, J. M., Bryant, G. A., Daly, M. W., Koenigsfeld, C. F., Lehman, N. P., Brueggen, K., McCormick, A., & Wellington, K. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020903816 · Cited by 9
Zhou, L., Zhang, Y., Tian, Y., Fu, X., Wang, L., & Xie, C. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-036268 · Cited by 14
Clegg, L. E., Jing, Y., Penland, R. C., Boulton, D. W., Hernandez, A. F., Holman, R. R., & Vora, J. P. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14313 · Cited by 9
Hallström, S., Hirsch, I. B., Ekelund, M., Sofizadeh, S., Albrektsson, H., Dahlqvist, S., Svensson, J., & Lind, M. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0577 · Cited by 9
“11 16–21 Moreover, different treatment regimens such as diet, sulfonylurea, and insulin have been found to affect glucose variability.”
InfluentialYang, K., Wang, H., Wei, R., Xiao, W., Tian, Q., Wang, C., Yang, J., & Hong, T. (2021) · Acta Diabetologica · doi:10.1007/s00592-020-01660-z · Cited by 9
Seasonal variation in estimated cardiovascular risk in patients with type 2 diabetes
Ciardullo, S., Muraca, E., Cannistraci, R., Manzoni, G., Perra, S., Bianconi, E., Oltolini, A., Zerbini, F., Grassi, G. M., Mancia, G., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.01.022 · Cited by 11
Wang, C., Lee, C., Hwang, Y., & Kuo, H. (2021) · LUTS Lower Urinary Tract Symptoms · doi:10.1111/luts.12384 · Cited by 9
Jiang, L., Xu, X., Luo, M.-H., Wang, H., Ding, B., Yan, R., Hu, Y., & Ma, J. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01151-6 · Cited by 10
An evaluation of canagliflozin for the treatment of type 2 diabetes: an update
Minami, T., Kameda, A., & Terauchi, Y. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1939675 · Cited by 10
Treating Diabetes to Prevent Stroke
Kernan, W. N., & Inzucchi, S. E. (2021) · Stroke · doi:10.1161/strokeaha.120.032725 · Cited by 9
Guo, L., Zhang, B., Hou, J., & Zhou, Z. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00869-z · Cited by 8
Li, X., Liu, L., Deng, Y., Li, Y., Zhang, P., Wang, Y., & Xu, B. (2020) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2020.1810263 · Cited by 8
Li, F., Li, G., Ren, J., Duan, J., Dong, J., & Liu, Z. (2023) · Scientific Reports · doi:10.1038/s41598-023-33211-1 · Cited by 8
“Cardiovascular and renal risk should be considered independently of HbA1c, and ADA standard (2022) places more emphasis on the consideration of cardiac and renal complications in drug selection 31–33 .”
King, A. B. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14265 · Cited by 8
Tan, F. H. S., Tong, C. V., Lau, B. K., Kuan, Y. C., Loh, H. H., & Pillai, S. V. (2021) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.036.02.11 · Cited by 8
Jung, H. H. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.22.005 · Cited by 9
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-12-16
- Volume
- 43
- Issue
- Supplement_1
- Pages
- S98-S110
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4246340431
- Cited by
- 914
- References
- 84
- Citations by year
- 2026: 17 · 2025: 39 · 2024: 69 · 2023: 100 · 2022: 151 · 2021: 270 · 2020: 268
- FWCI
- 140.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Glycemic Control, Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Hypoglycemic Agents, Reference Standards, Societies, Medical, United States, History, 21st Century, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.